With $165 million in the bank, Capstan Therapeutics launched Wednesday to combine the potency of cell therapy with the precision of genetic medicines against various difficult-to-treat diseases.
https://www.pharmalive.com/wp-content/uploads/2022/09/BioSpacepipettes9-14-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-14 09:00:172022-09-14 11:29:12Capstan Therapeutics launches with $165M for precise in vivo cell engineering
